Tumor tissue engineering has opened new avenues for cancer research. With an emphasis on gastrointestinal malignancies, we summarize capabilities and limitations of patient-derived and engineered organoid models. We then discuss how innovations in biomaterial design, biofabrication, microfluidics, benchmarking, and AI converge to better emulate tumor tissues and advance translational modeling.